PharmiWeb.com - Global Pharma News & Resources
19-Jul-2023

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET.



To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.

A live webcast of the call will be available on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including Acute Myeloid Leukemia, and for inflammatory diseases with high unmet needs. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is deployed to discover small molecule drugs--known as glycomimetics—that alter carbohydrate-mediated recognition in diverse disease states. As a leader in this science, GlycoMimetics leverages its unique approach to advance a pipeline of wholly-owned drug candidates with the goal of developing transformative therapies for diseases with high unmet need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.


Contacts

Investor Contact:
Argot Partners
Leo Vartorella
212-600-1902
Glycomimetics@argotpartners.com

Editor Details

  • Company:
    • Businesswire
Last Updated: 19-Jul-2023